Cardiff Oncology (CRDF) Other Non Operating Income (2011 - 2026)
Cardiff Oncology (CRDF) posted Other Non Operating Income of -$1000.0 for Q4 2025, little changed sequentially from -$1000.0 in Q2 2025, and up 50.0% YoY from -$666.67 in Q4 2024.
Cardiff Oncology (CRDF) Other Non Operating Income (2011 - 2026) Analysis & Trends
Cardiff Oncology has reported Other Non Operating Income for 15 years, with the latest figure at -$1000.0 in Q4 2025.
- Quarterly Other Non Operating Income rose 50.0% year-over-year to -$1000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $5000.0 (up 112.82% YoY) and the FY2025 annual result came in at $5000.0, up 112.82% from the prior year.
- Other Non Operating Income held at -$1000.0 in Q4 2025 per CRDF's latest filing, from -$1000.0 in the prior quarter.
- Over five years, Other Non Operating Income peaked at $270000.0 in Q4 2021 and troughed at -$253000.0 in Q2 2022.
- A 5-year average of -$1944.4 and a median of -$1500.0 in 2024 frame the typical range for Other Non Operating Income.
- The sharpest annual moves came in 2021 and 2022: Other Non Operating Income soared 10250.0% in 2021, then sank 1300.0% in 2022.
- Over 5 years, Other Non Operating Income stood at $270000.0 in 2021, then slumped by 116.67% to -$45000.0 in 2022, then soared by 71.11% to -$13000.0 in 2023, then soared by 84.62% to -$2000.0 in 2024, then jumped by 50.0% to -$1000.0 in 2025.
- According to Business Quant data, Other Non Operating Income over the past three periods registered -$1000.0, -$1000.0, and $7000.0 for Q4 2025, Q2 2025, and Q1 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Cardiff Oncology | 60.21 Mn | 60.21 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1,000.00 |
| Dec 31, 2025 | -1,000.00 |
| Jun 30, 2025 | -1,000.00 |
| Mar 31, 2025 | 7,000.00 |
| Dec 31, 2024 | -2,000.00 |
| Sep 30, 2024 | 5,000.00 |
| Jun 30, 2024 | -38,000.00 |
| Mar 31, 2024 | -4,000.00 |
| Dec 31, 2023 | -13,000.00 |
| Sep 30, 2023 | 21,000.00 |
| Jun 30, 2023 | 5,000.00 |
| Mar 31, 2023 | -111,000.00 |
| Dec 31, 2022 | -45,000.00 |
| Sep 30, 2022 | -36,000.00 |
| Jun 30, 2022 | -253,000.00 |
| Mar 31, 2022 | -49,000.00 |
| Dec 31, 2021 | 270,000.00 |
| Sep 30, 2021 | 3,000.00 |
| Mar 31, 2021 | 207,000.00 |
| Dec 31, 2020 | 158,000.00 |